Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428077 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00428077: Clinical Trial Phase 2 study, sponsored by OHSU Knight Cancer Institute.
NCT00428077 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00428077, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.
Primary Outcome
One-log decrease in circulating BCR-ABL transcripts (RT-PCR) that persists for at least three months during the 1-year treatment period.
Interventions
- GENETIC reverse transcriptase-polymerase chain reaction
- BIOLOGICAL bcr-abl peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Why NCT00428077 stopped before completion
NCT00428077 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which reverse transcriptase-polymerase chain reaction is the first listed.
NCT00428077 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00428077 about?
NCT00428077 is a clinical study titled "Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". RATIONALE: Vaccines made from a peptide may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with chronic phase chronic myelogenous leukemia.
What is the current status of trial NCT00428077?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2005-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00428077?
The interventions under investigation include: reverse transcriptase-polymerase chain reaction (GENETIC), bcr-abl peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00428077?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00428077's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia